CAMP4 Therapeutics
CAMP
61 hedge funds and large institutions have $182M invested in CAMP4 Therapeutics in 2026 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 7 closing their positions.
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
33% more funds holding
Funds holding: 46 → 61 (+15)
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
3.65% more ownership
Funds ownership: 76.62% → 80.27% (+3.6%)
4% more capital invested
Capital invested by funds: $176M → $182M (+$6.66M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.12M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.78M |
| 3 |
SC
SummitTX Capital
Fort Worth,
Texas
|
+$1.66M |
| 4 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$952K |
| 5 |
State Street
Boston,
Massachusetts
|
+$929K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ES
Enavate Sciences
Menlo Park,
California
|
-$3.3M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.48M |
| 3 |
6CM
683 Capital Management
New York
|
-$476K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$245K |
| 5 |
Millennium Management
New York
|
-$181K |
CAMP Hedge Fund Activity: Q2 2026 in Review
61 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in CAMP4 Therapeutics (CAMP) for Q2 2026, worth a combined $182M — up 3.8% from $176M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CAMP positions and 7 closed out — a net gain of 16 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $5.12M. The largest seller was Enavate Sciences, cutting an estimated $3.3M.
- 61 institutional investors held CAMP4 Therapeutics (CAMP) as of Q2 2026, up from 46 in Q1 2026.
- Funds reported $182M of CAMP4 Therapeutics stock for Q2 2026, up 3.8% quarter-over-quarter.
- 23 funds opened new CAMP4 Therapeutics positions in Q2 2026 and 7 closed out, a net change of +16 holders.
- The largest CAMP4 Therapeutics buyer in Q2 2026 was BlackRock, an estimated $5.12M added.
- The largest CAMP4 Therapeutics seller in Q2 2026 was Enavate Sciences, an estimated $3.3M sold.
Based on aggregated 13F filings for Q2 2026.